SCHEMBL653613

SCHEMBL653613

Nc1nc(-c2ccco2)cs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 1.00
HSD17B10 Q99714 8/20 1.00
CYP19A1 P11511 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.55
ALDH1A1 P00352 10/20 0.54
RAB9A P51151 6/20 0.54
PKM P14618 4/20 0.54
KDM4E B2RXH2 4/20 0.54
GFER P55789 1/20 0.54
KDM4C Q9H3R0 1/20 0.54
MEN1 O00255 7/20 0.51
KMT2A Q03164 7/20 0.51
ALOX15 P16050 4/20 0.51
BLM P54132 3/20 0.51
POLB P06746 2/20 0.51
CASP1 P29466 2/20 0.51
CASP7 P55210 2/20 0.51
LMNA P02545 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HPGD P15428 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7253210 0.80 CYP19A1 (0.72) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1
SCHEMBL1677340 0.80 MAPT (0.67) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1
SCHEMBL22761299 0.78 MAPT (0.64) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1
SCHEMBL3206574 0.75 MAPT (0.60) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1
SCHEMBL1677400 0.75 MAPT (0.60) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1
SCHEMBL8506147 0.75 MAPT (0.60) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1
SCHEMBL1677538 0.74 MAPT (0.59) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1
SCHEMBL13954988 0.74 MAPT (0.59) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1
SCHEMBL13955047 0.74 MAPT (0.59) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1
SCHEMBL14267937 0.74 MAPT (0.59) MAPTHSD17B10CYP19A1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010027564-A2 AMIDO ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLAXOSMITHKLINE LLC (US) 2010-03-11 WO claimed
US-20100061960-A1 Amido Anti-Viral Compounds, Compositions, And Methods Of Use SCHMITZ FRANZ ULRICH 2010-03-11 US claimed
US-20240175141-A1 BIOBASED AND BIODEGRADABLE CORROSION INHIBITION COMPOSITION ZestBio, Inc. 2024-05-30 US disclosed
WO-2024081967-A2 BIOBASED AND BIODEGRADABLE CORROSION INHIBITION COMPOSITION ZestBio, Inc. (US) 2024-04-18 WO disclosed
CN-104606190-B Agent for treating involuntary movement 协和发酵麒麟株式会社 2018-01-19 CN disclosed
US-20170334948-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV NOVALIX DEUTSCHLAND GMBH (DE) 2017-11-23 US disclosed
US-9745339-B2 Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV NOVALIX DEUTSCHLAND GMBH (DE) 2017-08-29 US disclosed
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 EP disclosed
EP-3002283-B1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO LTD (JP) 2017-06-14 EP disclosed
CN-102584813-B Compound and the purposes in regulating amyloid beta thereof NGC药物公司 2016-07-06 CN disclosed
EP-3002283-A1 THIAZOLE DERIVATIVES Kyowa Hakko Kirin Co., Ltd. (JP) 2016-04-06 EP disclosed
CN-1902196-A Thiazole derivatives KYOWA HAKKO KOGYO KK (JP) 2007-01-24 CN disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed
CN-1787822-A Compounds and their use in modulating amyloid beta TORREYPINES THERAPEUTICS INC (US) 2006-06-14 CN disclosed
EP-1628666-A2 COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA Torreypines Therapeutics, Inc. (US) 2006-03-01 EP disclosed
US-20050070538-A1 Compounds and uses thereof in modulating amyloid beta SIROCCO THERAPEUTICS, INC. 2005-03-31 US disclosed
WO-2004110350-A2 COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA TORREYPINES THERAPEUTICS, INC. (US) 2004-12-23 WO disclosed
EP-0321115-B1 CARBOXAMIDE DERIVATIVES HAVING TETRAZOLE AND THIAZOLE RINGS AND THEIR USE SAWAI PHARMACEUTICAL CO., LTD. (JP) 1991-08-14 EP disclosed
US-4946855-A ANTIALLERGIC SAWAI PHARMACEUTICAL CO., LTD. (JP) 1990-08-07 US disclosed
EP-0321115-A1 Carboxamide derivatives having tetrazole and thiazole rings and their use SAWAI PHARMACEUTICAL CO., LTD. (JP) 1989-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334948-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV FCGR1A, FCGR2A, FCGR3B MAPT 3952/4885HSD17B10 4170/4885CYP19A1 3224/4885
US-20100061960-A1 Amido Anti-Viral Compounds, Compositions, And Methods Of Use HAVCR2, OAT, MAVS MAPT 21/4885HSD17B10 4050/4885CYP19A1 4441/4885
US-20050070538-A1 Compounds and uses thereof in modulating amyloid beta APP, BACE1, BACE2 MAPT 10/4885HSD17B10 1824/4885CYP19A1 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.